GLIS2 and neoplasm: Collectively, because the C’ gene is silenced or lowly expressed in the corresponding normal lineage for promoter-hijacking-like fusions, we propose that corresponding C’ genes (RUNX1T1, PBX1, GLIS2, AFDN, FLI1, and MYH11) can serve as good drug targets because the expected “on-target, off-tumor” toxicity can be minimal to the normal cells of the corresponding lineage of cancer cells (but not for other normal cells where the C’ gene has housekeeping expression).